drugset / Trial / NCT00084279
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Consensus Interferon-Alpha | Unknown | 0.3 ml | Subcutaneous |
| Subject | Consensus Interferon-Alpha | Unknown | 0.5 ml | Subcutaneous |
| Subject | Interferon gamma-1b | Protein / enzyme biologic | 0.25 ml | Subcutaneous |
| Subject | Interferon gamma-1b | Protein / enzyme biologic | 0.5 ml | Subcutaneous |
| Subject | Ribavirin | Small molecule | — | — |